Penthrox Inhaler: Uses, Side Effects, and Availability

Penthrox is a handheld, disposable inhaler that delivers low-dose methoxyflurane, a fluorinated hydrocarbon with pain-relieving properties, for short-term relief of moderate to severe acute pain. It works fast, typically within minutes, and the patient controls it by breathing through the device. Originally developed decades ago as a general anesthetic, methoxyflurane fell out of favor after high anesthetic doses were linked to kidney damage. The modern Penthrox story is really about the rediscovery that much smaller inhaled doses can provide meaningful pain relief without the toxicity problems that ended its earlier career.

What Penthrox Is and How It Works

The Penthrox inhaler is a lightweight, pocket-sized plastic device loaded with a small bottle of liquid methoxyflurane (3 mL per unit). The patient inhales the vaporized drug through a mouthpiece while a one-way valve controls the dose. An activated-charcoal chamber on the back of the device captures most of the exhaled methoxyflurane, reducing secondhand exposure to bystanders and healthcare workers. The whole system is designed so that a patient in pain can use it without much coaching: you breathe in through the mouthpiece, and the drug vaporizes on contact with a wick inside the device.

Methoxyflurane acts on the central nervous system to dampen pain perception. At the low analgesic doses delivered by the Penthrox inhaler, it does not cause unconsciousness or full anesthesia. Patients stay alert and can still communicate, which is a practical advantage in emergency settings where monitoring resources are limited. Its ease of administration, fast onset, and portability make it well suited to prehospital care, where alternatives like intravenous morphine require needle access and nitrous oxide requires bulky cylinders.¹

Primary Uses in Trauma and Emergency Pain

The main approved use of Penthrox across most markets is emergency relief of moderate to severe pain associated with trauma in conscious adults. In the UK and Europe, methoxyflurane was approved for this indication, and it has become a staple in ambulance services throughout Australia and New Zealand, where it has been in use for decades. A systematic review of randomized controlled trials concluded that inhaled methoxyflurane provides rapid and effective pain relief for acute trauma, consistently outperforming placebo and standard treatments while improving both patient and clinician satisfaction.²

The phase III STOP! trial, one of the pivotal studies behind European approval, showed that methoxyflurane was effective and generally well tolerated for acute pain from minor trauma, with a rapid onset of analgesia. A separate prospective study found it was more effective than intramuscular tramadol for acute musculoskeletal pain in the prehospital setting, meaning paramedics could use it on scene rather than waiting until hospital arrival.³

Beyond acute injury, hospitals have found Penthrox useful for procedural pain during fracture manipulation and joint relocation. During the COVID-19 pandemic, one UK trauma center used it extensively to avoid general anesthesia and reduce operating theater use. Out of 54 fracture manipulations performed with Penthrox as the analgesic, all achieved adequate reduction. For joint dislocations, results varied by joint: elbow dislocations were reduced successfully in all four patients, while native shoulder dislocations succeeded in about two-thirds of cases.⁴

Expanding Into Procedural and Outpatient Settings

Penthrox is increasingly being studied and used for short painful procedures outside of the traditional emergency department. A systematic review of its outpatient and ambulatory applications found data covering a surprisingly wide range of elective procedures: colonoscopy, prostate biopsy, bone marrow aspiration, outpatient hysteroscopy, external fixator removal, and even nasoduodenal intubation for CT imaging.⁵ The appeal in these settings is the same as in emergency care: you hand the patient a device, they breathe through it, and within a few minutes the procedure becomes tolerable without the need for IV sedation, dedicated monitoring equipment, or a recovery room stay.

This matters for healthcare systems trying to reduce wait times and costs. Procedures that once required a sedation nurse and post-procedure observation can potentially be done in an outpatient clinic with the patient walking out shortly after. The trade-off is that Penthrox provides moderate analgesia rather than deep sedation, so it works best for procedures that are painful but brief, not for lengthy surgeries or interventions requiring the patient to be completely still.

How It Compares to Other Pain Relief Options

The question clinicians and patients care about most is how Penthrox stacks up against intravenous morphine and inhaled nitrous oxide, the two most common alternatives for acute pain in emergency settings.

Against IV morphine, the evidence points to a speed advantage for Penthrox in the first several minutes. In the MEDITA trial, a multicenter randomized study, patients with severe pain who received methoxyflurane achieved a significantly greater reduction in pain intensity compared to IV morphine during the first ten minutes. After that window, both treatments provided similar relief. The median time to onset of pain relief was about 9 minutes for methoxyflurane versus 15 minutes for morphine.⁶ A separate randomized trial in patients with acute limb fractures found comparable overall pain reduction between Penthrox and IV morphine, with a trend toward faster initial relief with Penthrox that did not reach statistical significance, plus a potential advantage in lower rates of nausea and vomiting.⁷

Against nitrous oxide (Entonox), the differences are smaller. A systematic review with an indirect treatment comparison found no significant differences between the two at 5, 10, or 15 minutes after inhalation, though the data trended slightly in favor of methoxyflurane. At the 15-minute mark, a slightly greater proportion of methoxyflurane patients reported pain relief, but the difference was not statistically significant.⁸ The practical difference comes down to logistics: Penthrox fits in a pocket and works in a wide temperature range, while nitrous oxide requires a pressurized cylinder and demand valve that are heavier and less portable.⁹

Common Side Effects

Penthrox is not side-effect free, but the effects patients experience tend to be mild and short-lived. In the STOP! trial, about 42% of patients receiving methoxyflurane reported at least one treatment-related side effect, compared to about 15% on placebo. The most common complaints were dizziness and headache. None of the adverse events caused patients to withdraw from the study, and the majority resolved quickly.¹⁰

The broader literature across multiple studies confirms a consistent pattern: adverse events are usually brief and self-limiting, with no clinically significant effects on vital signs like blood pressure, heart rate, or respiratory rate, and no meaningful impact on consciousness levels.¹¹ That said, a dizziness rate of roughly 40% is not trivial. Most patients using Penthrox are already lying down or sitting in an emergency department, which limits the practical consequences, but it is worth knowing about.

The Nephrotoxicity Question

This is the part of the Penthrox story that requires the most context, because methoxyflurane’s reputation was badly damaged in the 1970s and the shadow of that era still shapes how some clinicians view the drug.

When methoxyflurane was used as a general anesthetic in the 1960s and early 1970s, patients received it at far higher concentrations for far longer periods, often hours at a time. At those doses, the body metabolized enough methoxyflurane to release substantial amounts of inorganic fluoride, which caused a specific pattern of kidney tubular damage.¹² Classic dose-response work published in JAMA found that subclinical kidney toxicity occurred after about 2.5 to 3 MAC-hours of exposure, while frank clinical toxicity appeared at doses above 5 MAC-hours, corresponding to serum fluoride levels above certain thresholds.¹³ Earlier case reports had already linked high fluoride concentrations directly to kidney damage in individual patients.¹⁴

The analgesic dose delivered by a Penthrox inhaler is a tiny fraction of what was used for anesthesia. The total drug in one inhaler is 3 mL, and a patient can use a maximum of two inhalers (6 mL total) in a day. At these doses, nephrotoxicity has not been reported in the published literature.¹¹ A broad review of methoxyflurane’s analgesic use similarly concluded that no significant adverse effects have been reported when the dose stays within recommended limits, either in patients or in healthcare workers exposed occupationally.³

There are still reasonable cautions. The maximum daily and weekly dose limits exist precisely because the kidney risk is dose-dependent, and there is genuine uncertainty about safety in patients who already have impaired kidney function.¹⁵ Most prescribing guidance lists pre-existing significant renal impairment as a contraindication. The gap in the evidence is that there are not large studies specifically testing Penthrox in people with kidney disease, so the caution is largely theoretical but defensible given the drug’s history.

Use in Children and Adolescents

Penthrox has been studied in pediatric populations with encouraging results. A systematic review looking at six studies in children found that methoxyflurane provides effective and rapid analgesia for moderate to severe acute pain, is well tolerated, and is associated with good satisfaction ratings from both patients and healthcare providers.¹⁶

The MAGPIE trial, a large international randomized controlled trial, tested Penthrox against placebo in children and young people aged 6 to 17 with acute trauma pain.¹⁷ The results showed that methoxyflurane provided a greater reduction in pain scores compared to placebo at the 15-minute mark in children aged 9 to 17. Fewer children in the methoxyflurane group needed rescue medication (about 10% compared to 30% on placebo). The side-effect profile was broadly similar to what is seen in adults: dizziness was the most common complaint, occurring in about 41% of methoxyflurane recipients versus 12% on placebo, and euphoric mood was reported by about 12% of methoxyflurane users. No serious adverse events related to the drug were reported.¹⁸

For children specifically, the self-administered nature of the inhaler is appealing because it gives the child a sense of control. Anyone who has worked in pediatric emergency care knows that the fear of needles can be almost as distressing as the injury itself. An inhaler that the child holds and breathes through at their own pace removes that barrier entirely.

Use in Older Adults

Pain management in older adults is often complicated by polypharmacy, altered drug metabolism, and concerns about sedation leading to falls. A subgroup analysis of the MEDITA trial specifically examining patients aged 65 and over found that the benefits of methoxyflurane over standard care were consistent with the overall study population. The adverse event profile was mild: events in the methoxyflurane group included one case of vertigo, two of nausea, and one of drowsiness, all non-serious. There were no clinically significant changes in vital signs.¹⁹ A broader meta-analysis of pooled data also confirmed consistent findings in this age group.²⁰

This is a population where Penthrox may offer particular practical advantages. Establishing IV access in elderly patients with fragile veins can be slow and painful in itself. An inhaled analgesic that works quickly and does not require cannulation sidesteps that problem. The main concern specific to older adults remains kidney function, since age-related decline in renal capacity is common and the threshold for caution with methoxyflurane is correspondingly lower.

Where Penthrox Is Available

Penthrox’s availability varies considerably by country. Australia and New Zealand have the longest track record, where methoxyflurane has been used as a prehospital analgesic by paramedics for decades. It was approved in Europe in 2015 for moderate to severe trauma pain in adults, though uptake has been uneven. Despite that approval, it has still not become commonly used in parts of the United Kingdom.²¹

In the United States, Penthrox is not approved by the FDA. This is somewhat ironic given that the original kidney toxicity research that pulled methoxyflurane from anesthetic use was largely American. The regulatory path in the US has been complicated by the drug’s history and by the FDA’s separate evaluation framework. Other countries in the Middle East, parts of Asia, and Latin America have varying approval statuses, often following either the European or Australian regulatory model.

The uneven global availability creates a curious situation where emergency physicians at international conferences may be very familiar with Penthrox if they trained in Melbourne but have never seen one if they trained in New York. For travelers or military personnel, this patchwork means that a pain management option available on an ambulance in Sydney is simply not an option in many other health systems.

Cost and Workflow Considerations

From a health-system perspective, the cost of Penthrox is higher per patient than some alternatives. A UK prehospital study estimated that the additional cost per treated patient compared to nitrous oxide (Entonox) was about £12.30, reflecting the disposable nature of each Penthrox device versus the reusable cylinder-and-mask setup for nitrous oxide.²² That per-unit premium, however, needs to be weighed against downstream savings. If Penthrox allows a fracture to be reduced in the emergency department instead of an operating theater, the overall cost equation shifts dramatically. The COVID-era experience at UK trauma centers demonstrated exactly this kind of workflow gain, with procedures completed faster and without the overhead of full sedation teams.

For ambulance services, the portability argument is equally concrete. A Penthrox inhaler weighs almost nothing and takes up minimal space in a trauma kit. A nitrous oxide cylinder is heavy and bulky, and once depleted mid-shift, the paramedic is out of that option until they can resupply. Morphine requires IV access, which takes time and skill, and carries its own regulatory burden around controlled substance documentation. Penthrox slots into a gap where speed, simplicity, and portability all matter more than raw analgesic potency.

Limitations and Situations Where Penthrox Is Not Ideal

Penthrox is not a universal pain solution. Its analgesic ceiling is lower than that of opioids or ketamine, so for the most severe pain, such as major burns, multi-system trauma, or prolonged surgical procedures, it is typically a bridging measure rather than a definitive treatment. Patients often still need stronger analgesia once IV access is established or once they reach a facility with broader pain management options.

The dose limits also impose a time constraint. Each inhaler lasts roughly 25 to 30 minutes of intermittent use, and a maximum of two inhalers per day and per week means Penthrox cannot be used for ongoing pain management. It is strictly a short-term, acute-phase tool. Repeated use over consecutive days is contraindicated because of the cumulative fluoride exposure concern.

Contraindications include known hypersensitivity to fluorinated anesthetics, significant renal impairment, and a personal or family history of malignant hyperthermia (a rare but serious genetic reaction to certain anesthetics). Patients with cardiovascular instability or altered consciousness are also poor candidates, since the device requires the patient to be able to hold it and breathe through it voluntarily. If a patient becomes too drowsy or distressed to cooperate with inhalation, the self-limiting nature of the device actually serves as a built-in safety mechanism: they stop inhaling, and the drug delivery stops.

For clinicians considering Penthrox, the practical takeaway is that it fills a specific niche extremely well. That niche is moderate to severe acute pain of limited duration, in a conscious patient, where speed and simplicity are priorities. Outside that niche, it remains one tool among several rather than a replacement for the broader pain management toolkit.